Use of mesenchymal stem cell-derived exosome subpopulation s1 in the treatment of rapidly progressive interstitial lung disease

By isolating exosomes derived from mesenchymal stem cells into subpopulations, exosome subpopulation S1 was prepared for the treatment of rapidly progressive interstitial lung disease. This solved the problem of the lack of effective biological treatment methods in the existing technology and achieved the effect of significantly improving the oxygenation index and reducing inflammatory markers in patients.

CN122874492APending Publication Date: 2026-10-09P S K BIOSCIENCE CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202611090767.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-22
Publication Date
2026-10-09

AI Technical Summary

Technical Problem

Current technologies lack effective biological therapies for rapidly progressive interstitial lung disease (RP-ILD), especially in diseases with high inflammatory dynamics, where selective application studies are lacking. Exosome therapy also suffers from complex preparation processes and inconsistent efficacy.

Method used

By isolating exosomes derived from mesenchymal stem cells into subpopulations, the S1 component was obtained, and exosome drugs with higher bioactivity consistency were prepared for the treatment of rapidly progressive interstitial lung disease, including improving oxygenation index, reducing mortality, improving HRCT imaging, and reducing inflammatory markers.

Benefits of technology

Exosome subset S1 showed a faster trend toward functional improvement in highly inflammatory dynamics-induced RP-ILD, significantly improving patients' oxygenation index, reducing mortality, improving quality of life, and reducing inflammatory markers, without any drug-related serious adverse reactions.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present application relates to the technical field of stem cell exosome, and provides a use of mesenchymal stem cell-derived exosome subpopulation S1 in rapidly progressive interstitial lung disease (RP-ILD). On the basis of traditional immunosuppressive therapy, the exosome subpopulation S1 is inhaled by atomization, which can significantly improve the oxygenation index (OI) of patients, increase the survival rate, reduce the level of inflammatory factors, and improve the lung lesions of high-resolution CT (HRCT), and does not have any serious adverse reactions related to drug treatment. The present application provides a new treatment scheme for RP-ILD treatment, and has a good application prospect.
Need to check novelty before this filing date? Find Prior Art